Theralase Technologies (TLT) AI Stock Analysis

• Market Cap: C$53.98M
• Dividend Yield: N/A
• Average Volume (3M): 121.23K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.66
• Revenue Growth: 16.00%
• EPS Growth: 9.79%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 257,058,320
• 10 Day Avg. Volume: 149,922
• 30 Day Avg. Volume: 121,227
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.70
• Price Target Upside: 268.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Theralase Technologies' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis provides a neutral outlook, while valuation metrics highlight ongoing financial struggles. The absence of earnings call and corporate events data limits further insights.

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc. is a Canadian-based biotechnology company specializing in the development of innovative medical technologies, particularly in the field of photodynamic therapy (PDT) for cancer treatment and pain management. The company is focused on creating advanced therapeutic solutions that utilize its proprietary laser technology and drug formulations to improve patient outcomes in oncology and other health sectors.

How the Company Makes Money

Theralase generates revenue primarily through the commercialization of its proprietary laser systems and photodynamic therapy products. This includes the sale of medical devices, treatment protocols, and related consumables to healthcare providers. Additionally, the company may earn revenue through licensing agreements, partnerships with pharmaceutical companies, and potential collaborations for clinical trials. The establishment of strategic partnerships with medical institutions and research organizations enhances its market reach and supports the development of its products, further contributing to its revenue streams.

Theralase Technologies Financial Statement Overview

Summary

Theralase Technologies faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite low leverage, the reliance on external financing and negative profitability metrics indicate a need for strategic improvements.

Income Statement

Theralase Technologies has been experiencing declining revenue over the past few years, with a notable decrease from $1,138,569 in 2022 to $1,033,431 in 2024. The company has consistently reported negative net income, indicating ongoing losses. Gross profit margins have been low and deteriorating, reflecting challenges in cost management. The negative EBITDA and EBIT margins further highlight operational inefficiencies and lack of profitability.

Balance Sheet

The balance sheet shows a weakening position, with declining total assets and stockholders' equity over the years. The debt-to-equity ratio remains low due to minimal debt, which is a positive aspect. However, the equity ratio is declining, and the return on equity is negative due to continued losses, presenting a risk to financial stability.

Cash Flow

Theralase Technologies has been consistently generating negative operating cash flow and free cash flow, indicating struggles with generating cash from core operations. Free cash flow has shown some improvement in recent years but remains negative, highlighting cash management issues. Financing activities have been the primary source of cash, which could pose a risk if external funding becomes limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	1.03M	1.07M	1.14M	780.64K	929.12K
Gross Profit	595.91K	554.03K	562.13K	628.17K	309.94K	269.68K
EBITDA	-3.99M	-3.96M	-4.25M	-4.90M	-4.31M	-5.56M
Net Income	-4.28M	-4.26M	-4.57M	-5.25M	-4.42M	-5.61M
Balance Sheet
Total Assets	3.02M	3.25M	3.28M	4.16M	5.94M	10.02M
Cash, Cash Equivalents and Short-Term Investments	46.33K	268.76K	43.91K	1.51M	3.69M	7.88M
Total Debt	244.87K	293.87K	386.88K	473.62K	35.72K	92.34K
Total Liabilities	1.74M	1.18M	1.37M	1.07M	874.79K	857.13K
Stockholders Equity	1.28M	2.07M	1.91M	3.09M	5.07M	9.16M
Cash Flow
Free Cash Flow	-3.29M	-3.35M	-4.11M	-5.20M	-4.13M	-4.61M
Operating Cash Flow	-3.20M	-3.33M	-4.07M	-5.13M	-4.03M	-4.45M
Investing Cash Flow	-91.34K	-19.97K	-37.27K	-70.41K	-100.82K	-164.58K
Financing Cash Flow	2.91M	3.57M	2.65M	3.02M	-57.37K	-57.56K

Theralase Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TLT, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.20, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 41.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TLT.

Theralase Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASG	48 Neutral	C$23.42M	―	-26.27%	―	17.61%	-19.19%
PINK	46 Neutral	C$29.10M	-0.90	-233.44%	―	219.12%	-15.92%
TLT	45 Neutral	C$53.98M	-12.00	-291.69%	―	16.00%	9.79%
THRM	45 Neutral	C$4.26M	―	―	―	57.50%	16.20%
VPT	44 Neutral	C$15.93M	―	―	―	88.47%	11.88%
BLO	40 Underperform	$72.64M	-11.86	-188.03%	―	―	-52.41%

Theralase Technologies Corporate Events

Theralase’s Ruvidar® Shows Promise Against Herpes Simplex Virus

Theralase Technologies announced the publication of independent preclinical data showcasing the effectiveness of its antiviral candidate, Ruvidar®, in combating Herpes Simplex Virus Type 1 (HSV-1). The study highlights Ruvidar®’s superior performance compared to Acyclovir® and Metformin®, offering significant inhibitory effects on the virus without the need for light activation. This positions Ruvidar® as a promising next-generation antiviral therapy, particularly for drug-resistant HSV-1 infections, and supports its advancement into clinical development.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Extends Warrant Expiry to Bolster Market Position

Theralase Technologies Inc. announced the extension of the expiry date for 1,840,000 share purchase warrants from September 7, 2025, to September 7, 2028. This move, subject to approval by the TSX Venture Exchange, aims to provide the company with more time to potentially enhance its market position and operational capabilities, reflecting its ongoing commitment to advancing its therapeutic solutions.

Theralase Reports Q2 2025 Financials and Clinical Progress

Theralase Technologies Inc. has released its unaudited financial statements for the second quarter of 2025, reporting a 12% increase in total revenue to $310,933 and a 47% rise in gross margin to $131,967. Despite a slight increase in net loss to $2,423,235, the company has made significant strides in its Study II clinical trials, with 86 patients treated and promising interim results showing a 61.4% complete response rate. The company remains on track to complete enrollment by the third quarter of 2025, with regulatory submissions expected by the fourth quarter of 2026. Theralase has also completed several private placements to support its clinical and commercial milestones.